Last checked at 
| Tuesday 17 September | |
| JTC | Half Year Results |
| Staffline | Half Year Results |
| Personal Group | Half Year Results |
| Smart Metering Systems | Half Year Results |
| Uniphar | Half Year Results |
| Aquis Exchange | Half Year Results |
| Central Asia Metals | Half Year Results |
| French Connection Group | Half Year Results |
| Ocado Group | Q3 Results |
| Wednesday 18 September | |
| Kingfisher | Half Year Results |
| Accesso Technology | Half Year Results |
| Warpoint London | Half Year Results |
| Pendragon | Half Year Results |
| ClearStar | Half Year Results |
| Maxcyte | Half Year Results |
| Keywords Studios | Half Year Results |
| Bonhill Group | Half Year Results |
| Lloyd's of London | Half Year Results |
| Surgical Innovations | Half Year Results |
| Porvair | Trading Statement |
| Pan African Resources | Full Year Results |
| Thursday 19 September | |
| Clinigen Group | Full Year Results |
| Bluefields | Full Year Results |
| Cambridge Cognition | Half Year Results |
| Xeros Technology | Half Year Results |
| hVIVO | Half Year Results |
| City Pub Group | Half Year Results |
| Next | Half Year Results |
| Saga | Half Year Results |
| Lamprell | Half Year Results |
| Safestyle UK | Half Year Results |
| Kier Group | Full Year Results |
| IG Group | Q1 Results |
| Sound Energy | Half Year Results |
| Wilmington | Full Year Results |
| Friday 20 September | |
| Applegreen | Half Year Results |
| Smiths Group | Full Year Results |
| Hurricane Energy | Half Year Results |
| Investec | Trading Statement |
| Monday 23 September | |
| Brady | Half Year Results |
| Keystone Law | Half Year Results |
| PureCircle | Full Year Results |
| Faron Pharmaceuticals | Half Year Results |
| Billington Holdings | Half Year Results |
| Seeing Machines | Full Year Results |
| ASA International | Half Year Results |
| Oilex | Half Year Results |
| Microsaic Systems | Half Year Results |
| Instem | Half Year Results |
25 Aug 2021 11:43
Faron doses first patient in Covid-19 treatment trial
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.
Read more